{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-032289","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.641604+00:00","generated_at":"2026-05-17T01:32:33.405442+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"BioCardia enrolls first patient at Wisconsin in Phase 3 CardiAMP HF II trial","bullets":["First patient enrolled at University of Wisconsin School of Medicine and Public Health in Phase 3 CardiAMP HF II trial.","Trial is 250-patient randomized placebo-controlled study for ischemic HFrEF patients with elevated NTproBNP.","Dr. Amish Raval serves as national co-principal investigator; UW is a prestigious cardiology center.","Therapy uses autologous cells; cell population analysis defines doses; Helix system includes Morph DNA steerable platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-032289","json":"https://secwatch.observer/filing/0001437749-25-032289.json","markdown":"https://secwatch.observer/filing/0001437749-25-032289.md","text":"https://secwatch.observer/filing/0001437749-25-032289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774925032289/0001437749-25-032289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774925032289/bcda20251030_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:32:33.405442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}